CCCorey Casper

Corey Casper

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Corey Casper has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Anna Wald

    Division of Allergy and Infectious Diseases, Department of Medicine, Department of Epidemiology, Department of Laboratory Medicine and Pathology, University of Washington , Seattle, Washington

    9 shared publications
  • Lawrence Corey

    Department of Medicine, University of Washington 2 Department of Laboratory Medicine, University of Washington 4 Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center , Seattle, Washington

    6 shared publications
  • Elizabeth Krantz

    Fred Hutchinson Cancer Research Center, Seattle, WA

    3 shared publications
  • Jie Wang

    Department of Laboratory Medicine, University of Washington

    2 shared publications
  • John Pauk

    2 shared publications
  • Meei-Li Huang

    2 shared publications

Latest Publications

  • Correlates of cervical cancer screening from four Sub-Saharan African (SSA) countries: Results from the Demographic Health Survey (DHS)—2013-2015.

    by Manoj Menon, Elizabeth Krantz, Corey Casper

    E18006 Background: Widespread cervical cancer screening has led to a dramatic reduction in cervical-cancer related mortality in resource-rich regions. However, cervical cancer remains a leading cause of cancer-related death in SSA due in part to a lack of accessible screening and treatment options. Methods: The DHS is a nationally representative household survey designed by ICF International and typically implemented every 5 years. In addition to demographic characteristics, select surveys collect data on cervical cancer awareness and screening. We included women aged ≥21 years from Côte d'Ivoire, Kenya, Namibia, and Zimbabwe who participated in the DHS. After sample weights were applied, we used logistic regression to examine associations of demographics and national cervical cancer incidence (as per the International Agency on Research on Cancer) with cervical cancer screening. Factors with p < 0.20 in bivariate analyses were included in a multivariate model. Results: We analyzed data from 45,947 women aged 21 to 49 years (mean = 32.2); 69% were married with an average of 3 children. Nearly half had completed secondary education (47%), 73% were literate, and 48% belonged to the highest two wealth quintiles. Over 70% of women were aware of cervical cancer; 24% of all women reported a previous screening exam with variation by country. Namibia, with the highest rates of screening (46%), had the lowest incidence. In multivariate analyses, cervical cancer screening was associated with increasing age (OR = 1.06; CI = 1.05, 1.07), education (OR = 1.48; CI = 1.30, 1.69), literacy (OR = 1.80; CI = 1.53, 2.13), and wealth (OR = 1.14; CI = 1.09, 1.20). Higher cervical cancer incidence at the national level (OR = .980; CI = .976, .983) and rural residence (OR = .839; CI = .738, .953) were inversely associated with odds of cervical cancer screening. Conclusions: Based on DHS data from four SSA countries, awareness of cervical cancer is high, but receipt of cervical cancer screening is low and may be associated with reductions in cervical cancer incidence. Targeted efforts to increase utilization of cervical cancer screening in SSA are warranted to reduce the preventable burden of cervical cancer.


  • Open Access

    Valganciclovir for Suppression of Human Herpesvirus–8 Replication: A Randomized, Double‐Blind, Placebo‐Controlled, Crossover Trial

    by Corey Casper, Elizabeth M. Krantz, Lawrence Corey, Steven R. Kuntz, Jie Wang, Stacy Selke, Shannon Hamilton, Meei‐Li Huang, Anna Wald

    Background. Human herpesvirus–8 (HHV-8) replication is critical in the induction and maintenance of Kaposi sarcoma, primary effusion lymphoma, and so


  • Open Access

    Frequent and Asymptomatic Oropharyngeal Shedding of Human Herpesvirus 8 among Immunocompetent Men

    by Corey Casper, Elizabeth Krantz, Stacy Selke, Steven R. Kuntz, Jie Wang, Meei‐Li Huang, John S. Pauk, Lawrence Corey, Anna Wald

    BackgroundLittle is known about the clinical and virologic manifestations of human herpesvirus (HHV)–8 infection in immunocompetent persons in the ab


  • The Use of Antiviral Drugs in the Prevention and Treatment of Kaposi Sarcoma, Multicentric Castleman Disease and Primary Effusion Lymphoma

    by C. Casper, A. Wald

    Kaposi sarcoma-associated herpesvirus [KSHV, also known as human herpesvirus 8 (HHV-8)] is the most recently identified member of the human herpesvirus family. Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease are all associated with KSHV infection. Although the incidence of KS has declined dramatically in areas with access to highly active antiretroviral therapy, it remains the most common AIDS-associated malignancy in the developed world and is one of the most common cancers in developing nations. Current treatment options for KSHV-associated disease are ineffective, unavailable, or toxic to many affected persons. A growing body of basic science, preclinical, and observational data suggests that antiviral medications may play an important role in the prevention and treatment of KSHV-associated disease.


  • Open Access

    Human Herpesvirus 8 Infection Among Adolescents in the REACH Cohort

    by Corey Casper, Amalia S. Meier, Anna Wald, Rhoda Ashley Morrow, Lawrence Corey, Anna-Barbara Moscicki

    Objective Human herpesvirus 8 (HHV-8) infection is common among children in areas where Kaposi sarcoma is endemic. Human herpesvirus 8 is uncommon in children but prevalent in adults at risk for human immunodeficiency virus (HIV) infection in the United States, including men who have sex with men (MSM) and women who engage in high-risk sexual behavior. We examined the prevalence and predictors of HHV-8 infection among adolescents with or at high risk for acquiring HIV infection. Design Cross-sectional analysis. Setting National study of HIV infection among adolescents in primary care. Participants A total of 537 young adults practicing high-risk sexual behavior, of which 403 were women and 134 were men; among the 134 men, 75% were MSM. Interventions Detailed questionnaires and testing for serum antibodies to HHV-8. Outcome Measure Detection of serum antibodies to HHV-8. Results Sixty (11.2%) of 537 young adults were HHV-8 seropositive, including 20 MSM (19.6%), 2 male heterosexuals (6.5%), and 27 female heterosexuals (8.2%). The prevalence of HHV-8 in HIV-positive MSM (17/74 [23.0%]) was twice as high as that in HIV-negative MSM (3/28 [10.7%]) (P = .18), but no characteristic predicted HHV-8 infection among MSM. In multivariate analysis, history of gonorrhea (odds ratio [OR], 2.8; 95% confidence interval [CI], 1.4-5.7;P<.01), history of having sex with women (OR, 2.4; 95% CI, 1.1-5.3;P = .03), and African American race (OR, 3.4; 95% CI, 1.1-10.0;P = .03) were associated with HHV-8 infection among women. Conclusions Human herpesvirus 8 is common among US adolescents practicing high-risk sexual behaviors. Sexual identity, race, and sexual behavior may influence the risk of infection with HHV-8 in women.


    • 1 August 2006
      • Vol. 13  (2) , 42-7

    Defining a role for antiviral drugs in the treatment of persons with HHV-8 infection.

    by C Casper

    Human herpesvirus type 8 (HHV-8) is the most recently identified member of the human herpesvirus family and the aetiological agent of Kaposi's sarcoma, primary effusion lymphoma and multicentric Castleman's disease. While highly active antiretroviral therapy has led to impressive declines in the incidence of Kaposi's sarcoma, HHV-8- associated infections remain common and morbid across the globe. Although comprehensive clinical trials of therapy for HHV-8-associated infections are lacking, numerous studies have found current treatment modalities to be ineffective for many patients. A growing body of basic scientific and clinical work suggests that antiviral drugs may have a role in the treatment and (more significantly) in the prevention of HHV-8-associated infections. This review discusses current evidence for the efficacy of antivirals against HHV-8 and proposes novel uses for such medications in HHV-8 treatment.


  • HIV serodiscordant sex partners and the prevalence of human herpesvirus 8 infection among HIV negative men who have sex with men: baseline data from the EXPLORE Study

    by C Casper

    Human herpesvirus 8 (HHV-8) infection is common among men who have sex with men (MSM), especially those infected with HIV, and is frequently detected in saliva. We sought to determine whether oral or anogenital contact with HIV discordant, or unknown serostatus sexual partners is associated with HHV-8 seroprevalence among HIV negative MSM. HIV negative MSM participating in a behavioural intervention trial for the prevention of HIV infection (the EXPLORE study) were recruited from the Seattle and Denver areas for participation in this cross sectional study. Participants completed detailed questionnaires regarding sexual behaviour, focusing on activities with possible exposure to the oropharynx. Serum samples from study enrollment were tested for the presence of HHV-8 antibodies using whole virus enzyme immunoassay and immunofluorescence assay to latent and lytic proteins. 198/819 MSM (24.3%) were HHV-8 antibody positive. Exposure to saliva with HIV positive and HIV unknown serostatus sex partners was reported by 83% and 90% of all men, respectively. In a multivariate model, reporting more than the median number of lifetime sex partners (OR 2.2, p = 0.03) or lifetime sex partners of unknown HIV status (OR 1.7, p = 0.03), and the performance of oro-anal sex ("rimming") on partners whose HIV status is unknown (OR 2.7, p = 0.04) were independently associated with HHV-8 infection. The oropharynx may be an important anatomical site in HHV-8 acquisition, and contact with HIV serodiscordant or unknown sex partners is associated with higher HHV-8 seroprevalence among HIV negative MSM.


  • The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care

    by Corey Casper

    Summary: Fifty years ago, Dr Benjamin Castleman first described the unusual lymphoproliferative disorder that now bears his name. Over the subsequent decades, astute clinical and pathologic observations coupled with clever molecular biologic research have increased our understanding of the aetiology of Castleman disease (CD). This article proposes three broad CD variants based on both distinctive histopathology and clinical behaviour. The pivotal roles of infection with human herpesvirus 8 and interleukin‐6 production in the development of CD are emphasized. Finally, the natural history of CD and the myriad of therapeutic options are reviewed in the context of a unified model of CD pathophysiology, and continued areas of uncertainty are discussed.


  • HIV Infection and Human Herpesvirus-8 Oral Shedding Among Men Who Have Sex with Men

    by Corey Casper, Mary Redman, Meei-Li Huang, John Pauk, Thomas M. Lampinen, Stephen E. Hawes, Cathy W. Critchlow, Rhoda Ashley Morrow, Lawrence Corey, Nancy Kiviat, et al.

    Human herpesvirus-8 (HHV-8) is frequently detected in oropharyngeal secretions from HIV-infected men who have sex with men (MSM), and contact with saliva may be an important mode of HHV-8 transmission. A total of 196 MSM were followed over 2 years to determine the correlates of HHV-8 oropharyngeal shedding. A total of 134 (68%) of 196 participants were HHV-8 seropositive upon enrollment, and 9 (15%) of 62 participants seroconverted to HHV-8 during follow-up. HHV-8 DNA was detected in 43 (22%) of 196 participants: 39 (27%) of 134 HHV-8 seropositive, 4 (8%) of 53 HHV-8 seronegative, and 5 (56%) of 9 seroconverters to HHV-8. HHV-8 was detected in 101 (15%) of 696 total oral specimens: 84 (17%) of 481 samples from HHV-8–seropositive men, 6 (3%) of 180 samples from HHV-8–seronegative men, and 11 (31%) of 35 samples from seroconverters. Using adjusted marginal structural models, HHV-8 shedding was higher in men not receiving highly active antiretroviral therapy (odds ratio 2.4, 95% CI 1.0–6.0, P = 0.06), with CD4 counts > 200 cells/mm3 (odds ratio 4.8, 95% CI 1.0–22.8, P = 0.05), or with detectable oral leukocyte esterase (odds ratio 5.0, 95% CI 2.0–12.5, P < 0.01). CD4 count, antiretroviral therapy, and oral inflammation may influence HHV-8 oropharyngeal shedding.


  • Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment

    by Corey Casper, W. Garrett Nichols, Meei-Li Huang, Lawrence Corey, Anna Wald

    Multicentric Castleman disease (MCD) is a lymphoproliferative disorder associated with human herpesvirus 8 (HHV-8) infection among persons with human immunodeficiency virus (HIV) infection. Treatment often includes chemotherapy, and progression to non-Hodgkin lymphoma frequently occurs. MCD is characterized in part by active HHV-8 replication, and many of the symptoms of MCD may be attributable to viral gene products. We describe the effect of ganciclovir on the clinical and virologic course of MCD in a series of 3 case reports. Two patients experienced a reduction in the frequency of episodic flares of MCD and detectable HHV-8 DNA with intravenous or oral ganciclovir, whereas the third patient recovered from an acute episode of renal and respiratory failure with intravenous ganciclovir therapy. These data provide in vivo evidence for the utility of antiviral agents against HHV-8 in the management of MCD.